- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05052437
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
Open, Multicenter, Phase Ic Clinical Study on the Pharmacokinetics and Drug Interactions of Utidelone Plus Capecitabine in Patients With Recurrent and Metastatic Breast Cancer
This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.
The purpose of this trial is:
- To evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone.
- To evaluate the drug interaction of utidelone and capecitabine.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China
- Hunan Cancer Hospital
-
Changsha, Hunan, China
- The Third Xiangya Hospital of Central South University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntarily sign an informed consent form, have good compliance, and cooperate with relevant inspections.
- Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer.
- Patients who have previously received at least one anthracycline and taxane drug therapy (neoadjuvant therapy, adjuvant therapy, or recurrence and metastasis therapy), or the investigator believes that they can be included in this study.
- Age ≥18 years; physical condition score ECOG 0~2 points.
- Within 4 weeks before enrollment, Neuropathy should be less than grade 2 (NCI CTCAE 5.0).
Within 1 week before enrollment, routine blood examinations were basically normal (based on the normal value of each research center laboratory):
- White blood cell count (WBC) ≥3.0×109/L;
- Neutrophil count (ANC) ≥ 1.5×109/L;
- Platelet count (PLT) ≥100×109/L.
- Hemoglobin ≥9g/dL.
Within 1 week before enrollment, liver and kidney function tests were basically normal (the normal value of each research center laboratory is standard):
- Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN);
- Alanine aminotransferase (SGPT/ALT)≤2.5×ULN (for liver metastases≤5×ULN);
- Aspartate aminotransferase (SGOT/AST)≤2.5×ULN (for liver metastases≤5×ULN);
- Creatinine clearance rate (Ccr) ≥60 ml/min.
- No major organ dysfunction.
- The patient must agree to provide blood, urine and stool samples for pharmacokinetic studies, and collect them in strict accordance with the required time points and intervals.
- No mental abnormality, able to understand and undertake informed consent.
Exclusion Criteria:
- Those who need to receive non-investigative anti-cancer therapy (such as chemotherapy, immunotherapy or biological therapy) during the administration period of this trial.
- People who are severely allergic to castor oil, or who have had serious adverse reactions to anti-microtubule drugs in the past.
- Within 4 weeks before receiving treatment, have had any major surgery or suffered major trauma; or are expected to undergo major surgery during the treatment.
- Pregnancy (positive pregnancy test), breastfeeding patients, or those who are unwilling to use contraception during the test;
- Those with uncontrollable intracranial hypertension syndrome (persistent headache, short-term blurred vision, and/or diplopia)
- Combined serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, severe infection, active peptic ulcer, etc.
- Known HIV infection, or untreated active hepatitis B or C;
- Known to have alcohol or drug addiction, or have a history of uncontrollable mental illness, lack of legal capacity or limited legal capacity;
- The investigator believes that it is inappropriate to participate in this trial.
- Participate in another clinical trial or use other research treatments at the same time.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Utidelone
|
8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
|
Experimental: Utidelone plus capecitabine
|
8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine.
Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days.
21 days is a cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Plasma Concentration (Cmax)
Time Frame: 12 weeks
|
To measure the maximal plasma concentration of the study drugs and evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone, measure PK parameters such as Maximum Plasma Concentration [Cmax]
|
12 weeks
|
C-T curve
Time Frame: 12 weeks
|
To evaluate the pharmacokinetic interaction of utidelone and capecitabine in patients when administered in combination.
|
12 weeks
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: 12 weeks
|
To get area under the plasma concentration versus time curve
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure and plot r-t curve
Time Frame: 12 weeks
|
To analyse mass balance
|
12 weeks
|
Incidence of treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 6 months
|
To evaluate the safety of the study
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Quchang Ouyang, MD, Hunan Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BG01-2001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced and Metastatic Breast Cancer
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
National Center of Oncology, ArmeniaBRIU GmbHCompletedAdvanced Breast Cancer | Metastatic Breast CancerArmenia
-
SanofiCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast CancerUnited States
Clinical Trials on Utidelone
-
Henan Cancer HospitalRecruiting
-
Beijing Biostar Pharmaceuticals Co., Ltd.Chengdu Biostar PharmaceuticalsRecruiting
-
Biostar Pharma, Inc.RecruitingAdvanced Solid TumorUnited States
-
Fudan UniversityNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast Cancer
-
Beijing Biostar Pharmaceuticals Co., Ltd.Chengdu Biostar PharmaceuticalsSuspendedAdvanced or Metastatic CRCChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingMetastatic Urothelial CarcinomaChina
-
Beijing Biostar Pharmaceuticals Co., Ltd.Chengdu Biostar PharmaceuticalsCompletedAdvanced Non-small Cell Lung CancerChina
-
Beijing Biostar Pharmaceuticals Co., Ltd.RecruitingAdvanced Solid TumorChina
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Sun Yat-sen UniversityHunan Cancer Hospital; Beijing Biostar Pharmaceuticals Co., Ltd.RecruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina